随着免疫检查点抑制剂(ICIs)在肿瘤治疗领域的广泛应用,其引发的免疫相关不良反应(irAEs)也备受关注。irAEs可发生于全身任何器官系统,其中以肌肉骨骼表现为主的风湿性irAEs在临床中常有报道,如炎性关节炎、风湿性多肌痛、肌炎、血管炎...随着免疫检查点抑制剂(ICIs)在肿瘤治疗领域的广泛应用,其引发的免疫相关不良反应(irAEs)也备受关注。irAEs可发生于全身任何器官系统,其中以肌肉骨骼表现为主的风湿性irAEs在临床中常有报道,如炎性关节炎、风湿性多肌痛、肌炎、血管炎等,早期识别和干预此类不良反应对改善肿瘤患者预后尤为重要,而寻找有助于精确预测irAEs发生的生物标志物也成为未来研究的热点。因此,本文就ICIs相关风湿性不良反应的临床特点、诊断和鉴别诊断、管理及潜在预测性标志物加以综述,以加强临床医师对此类疾病的认识。With the wide application of immune checkpoint inhibitors (ICIs) in the field of tumor therapy, the immune-related adverse events (irAEs) induced by ICIs have also attracted much attention. The irAEs can occur in any organ system, among which rheumatic irAEs which are mainly characterized by musculoskeletal manifestations have often been reported in clinic, such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis. Early identification and intervention of these adverse events are important for improving prognosis of cancer patients. Finding biomarkers that can help to accurately predict the development of irAEs will be a focus of future research. Therefore, this article reviews the clinical features, diagnosis, differential diagnosis, management and potential predictive markers of ICIs-associated rheumatic adverse events to enhance clinicians’ understanding of these diseases.展开更多
文摘随着免疫检查点抑制剂(ICIs)在肿瘤治疗领域的广泛应用,其引发的免疫相关不良反应(irAEs)也备受关注。irAEs可发生于全身任何器官系统,其中以肌肉骨骼表现为主的风湿性irAEs在临床中常有报道,如炎性关节炎、风湿性多肌痛、肌炎、血管炎等,早期识别和干预此类不良反应对改善肿瘤患者预后尤为重要,而寻找有助于精确预测irAEs发生的生物标志物也成为未来研究的热点。因此,本文就ICIs相关风湿性不良反应的临床特点、诊断和鉴别诊断、管理及潜在预测性标志物加以综述,以加强临床医师对此类疾病的认识。With the wide application of immune checkpoint inhibitors (ICIs) in the field of tumor therapy, the immune-related adverse events (irAEs) induced by ICIs have also attracted much attention. The irAEs can occur in any organ system, among which rheumatic irAEs which are mainly characterized by musculoskeletal manifestations have often been reported in clinic, such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis. Early identification and intervention of these adverse events are important for improving prognosis of cancer patients. Finding biomarkers that can help to accurately predict the development of irAEs will be a focus of future research. Therefore, this article reviews the clinical features, diagnosis, differential diagnosis, management and potential predictive markers of ICIs-associated rheumatic adverse events to enhance clinicians’ understanding of these diseases.
